Royal Philips


Incorporating some potential obstacles arising from recent Chinese developments

15/09/23 -"Despite Philips gaining confidence, thanks to promising testing results for respiratory devices, improving operations and a big new investor coming on board, our target price resets lower due to ..."

Pages
65
Language
English
Published on
15/09/23
You may also be interested by these reports :
19/06/24
Taking into consideration the management’s recent guidance downgrade due to the ongoing weakness in China and delay in interest rate cuts in the US, ...

18/06/24
Surprisingly, CZM slashed its full-year guidance yesterday. Greater Chinese exposure (marred by VBP roll-out delays and softer start to the summer ...

13/06/24
The group has completed the first tranche of its planned recap and will launch the second one, with a deep discount (65% on the closing price as of ...

13/06/24
We have incorporated the reserved capital increase of €92.1m into our market cap calculation, following its completion on 12/06/2024. Note that we ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO